Pursuing FDA regulatory clearance for AppyScore™
Company: Riot
The claim, verbatim
The company is pursuing receipt of regulatory clearance for and commercialization of AppyScore™, its blood-based diagnostic test for appendicitis
Source (primary)
Riot DEF 14A filed 2012-10-15 (SEC EDGAR, sec_filing)
View cached copy (2026-09-27)Live source ↗
Quote: “pursuit of receipt of regulatory clearance for and commercialization of the Company's blood-based diagnostic test to aid emergency room physicians and other practitioners in the identification of patients at low risk for acute appendicitis”
How we checked this
Checked on September 30, 2026. The cited source supports every part of this claim.
The filing says the company refocused on obtaining regulatory clearance for and commercializing AppyScore, its blood-based appendicitis test.
Confirmed in the source:
- The company is pursuing regulatory clearance for its blood-based appendicitis diagnostic test
- The company is pursuing commercialization of that test
- The test is AppyScore, identified as the company's lead product candidate
What we did: Read our cached copy of SEC EDGAR (https://www.sec.gov/Archives/edgar/data/1167419/000107997312000796/appy_def14a.htm) in full (92,836 characters, retrieved September 27, 2026) and checked each assertion in the claim against it.
Additional evidence
confirms Riot DEF 14A filed 2012-10-15
Quote: “pursuit of receipt of regulatory clearance for and commercialization of the Company's blood-based diagnostic test to aid emergency room physicians and other practitioners in the identification of patients at low risk for acute appendicitis”